Moleculin Biotech shares are trading lower. The company announced a best‑efforts public offering of stock and warrants, including pre‑funded options to cap ownership.

Benzinga Newsdesk www.benzinga.com Neutral 61.1%

Neg 0% Neu 61.1% Pos 0%

Comments

No comments yet. Be the first!